Product
name: LMWP
Sequence:
VSRRRRRRGGRRRR
Purity: 95% by
HPLC
Counter
ion: Trifluoacetate
Format: Lyophilized
powder
Description: Low molecular weight
protamine (LMWP) is a peptide fragment produced in our laboratory from enzymatic
digestion of native protamine. More than 30 papers studying the properties and
applications of LMWP have been published by our group in various journals since
its initial discovery in 1999. Results have shown that LMWP could completely
neutralize the anticoagulant functions of both heparin and low molecular weight
heparin (LMWH), with reduced antigenicity and cross-reactivity toward the
mice-derived anti-protamine antibodies. Aside from its potential as a
heparin/LMWH antagonist, LMWP also shows the ability to retard insulin
adsorption by the formation of an insoluble complex, making it a less toxic
long-lasting insulin product than the conventional neutral protamine Hagedorn
(NPH) insulin for diabetic control. Importantly, LMWP (Sequence:
VSRRRRRRGGRRRR), with 10 arginine residues in its structure, could function as a
cell-penetrating peptide (CPP), also termed protein transduction domain (PTD),
to achieve effective intracellular protein or gene delivery in clinical
practice. In this paper, we present a thorough review of our work related to
LMWP, with the aim of providing readers an insight into its potential to be a
clinical protamine substitute as well as a non-toxic cell penetrating peptide
applicable to achieve intracellular protein and gene
delivery.
Usage: For
Scientific Research Use Only, Not for Human Use.
Reference:
Journal of
Controlled Release.Volume 193, 10 November 2014, Pages
63–73.